Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Corrona Psoriasis (PSO) Registry

Trial Profile

Corrona Psoriasis (PSO) Registry

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Jun 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary) ; Apremilast (Primary) ; Brodalumab (Primary) ; Ciclosporin (Primary) ; Etanercept (Primary) ; Guselkumab (Primary) ; Infliximab (Primary) ; Ixekizumab (Primary) ; Methotrexate (Primary) ; Secukinumab (Primary) ; Ustekinumab (Primary)
  • Indications Plaque psoriasis; Psoriasis; Psoriatic arthritis
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Jun 2020 Results (As of May 10 2018; n=4864) assessing effectiveness of secukinumab with regard to clinical and patient-reported outcomes from enrollment to a 6-month follow-up visit in patients with psoriasis in the Corrona Psoriasis Registry, published in the Journal of Dermatological Treatment
    • 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 13 Sep 2018 According to a Novartis media release, data from the study evaluating Cosentyx, has been presented at the 27th European Academy of Dermatology and Venereology (EADV) Congress 2018.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top